Update on the profile of the EUSTAR cohort

An analysis of the EULAR Scleroderma Trials and Research group database

Florian M P Meier, Klaus W. Frommer, Robert Dinser, Ulrich A. Walker, L. Czirják, Christopher P. Denton, Yannick Allanore, Oliver Distler, Gabriela Riemekasten, Gabriele Valentini, Ulf Müller-Ladner

Research output: Contribution to journalArticle

133 Citations (Scopus)

Abstract

Objectives: Systemic sclerosis (SSc) is a rare disease requiring multicentre collaboration to reveal comprehensive details of disease-related causes for morbidity and mortality. Methods: The European League Against Rheumatism (EULAR) Scleroderma Trials and Research (EUSTAR) group initiated a database to prospectively gather key data of patients with SSc using a minimal essential dataset that was reorganised in 2008 introducing new items. Baseline visit data of patients who were registered between 2004 and 2011 were analysed using descriptive statistics. Results: In June 2011, 7655 patients (2838 with diffuse cutaneous (dc) and 4481 with limited cutaneous (lc) SSc who fulfilled the American College of Rheumatology diagnostic criteria had been registered in 174 centres, mainly European. The most prominent hallmarks of disease were Raynaud's phenomenon (96.3%), antinuclear antibodies (93.4%) and a typical capillaroscopic pattern (90.9%). Scleroderma was more common on fingers and hands than on any other part of the skin. Proton pump inhibitors (65.2%), calcium channel blockers (52.7%), and corticosteroids (45.3%) were most often prescribed. Among the immunosuppressant agents, cyclophosphamide was used more often in dcSSc than in lcSSc. Conclusions: The EUSTAR database provides an abundance of information on the true clinical face of SSc that will be helpful in improving the classification of SSc and its subsets and for developing more specific therapeutic recommendations.

Original languageEnglish
Pages (from-to)1355-1360
Number of pages6
JournalAnnals of the Rheumatic Diseases
Volume71
Issue number8
DOIs
Publication statusPublished - Aug 2012

Fingerprint

Systemic Scleroderma
Rheumatic Diseases
Cohort Studies
Databases
Research
Proton Pump Inhibitors
Antinuclear Antibodies
Skin
Calcium Channel Blockers
Immunosuppressive Agents
Cyclophosphamide
Adrenal Cortex Hormones
Raynaud Disease
Statistics
Rare Diseases
Fingers
Hand
Morbidity
Mortality

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Allergy

Cite this

Update on the profile of the EUSTAR cohort : An analysis of the EULAR Scleroderma Trials and Research group database. / Meier, Florian M P; Frommer, Klaus W.; Dinser, Robert; Walker, Ulrich A.; Czirják, L.; Denton, Christopher P.; Allanore, Yannick; Distler, Oliver; Riemekasten, Gabriela; Valentini, Gabriele; Müller-Ladner, Ulf.

In: Annals of the Rheumatic Diseases, Vol. 71, No. 8, 08.2012, p. 1355-1360.

Research output: Contribution to journalArticle

Meier, FMP, Frommer, KW, Dinser, R, Walker, UA, Czirják, L, Denton, CP, Allanore, Y, Distler, O, Riemekasten, G, Valentini, G & Müller-Ladner, U 2012, 'Update on the profile of the EUSTAR cohort: An analysis of the EULAR Scleroderma Trials and Research group database', Annals of the Rheumatic Diseases, vol. 71, no. 8, pp. 1355-1360. https://doi.org/10.1136/annrheumdis-2011-200742
Meier, Florian M P ; Frommer, Klaus W. ; Dinser, Robert ; Walker, Ulrich A. ; Czirják, L. ; Denton, Christopher P. ; Allanore, Yannick ; Distler, Oliver ; Riemekasten, Gabriela ; Valentini, Gabriele ; Müller-Ladner, Ulf. / Update on the profile of the EUSTAR cohort : An analysis of the EULAR Scleroderma Trials and Research group database. In: Annals of the Rheumatic Diseases. 2012 ; Vol. 71, No. 8. pp. 1355-1360.
@article{2362f28c689e4507bde68f3113575919,
title = "Update on the profile of the EUSTAR cohort: An analysis of the EULAR Scleroderma Trials and Research group database",
abstract = "Objectives: Systemic sclerosis (SSc) is a rare disease requiring multicentre collaboration to reveal comprehensive details of disease-related causes for morbidity and mortality. Methods: The European League Against Rheumatism (EULAR) Scleroderma Trials and Research (EUSTAR) group initiated a database to prospectively gather key data of patients with SSc using a minimal essential dataset that was reorganised in 2008 introducing new items. Baseline visit data of patients who were registered between 2004 and 2011 were analysed using descriptive statistics. Results: In June 2011, 7655 patients (2838 with diffuse cutaneous (dc) and 4481 with limited cutaneous (lc) SSc who fulfilled the American College of Rheumatology diagnostic criteria had been registered in 174 centres, mainly European. The most prominent hallmarks of disease were Raynaud's phenomenon (96.3{\%}), antinuclear antibodies (93.4{\%}) and a typical capillaroscopic pattern (90.9{\%}). Scleroderma was more common on fingers and hands than on any other part of the skin. Proton pump inhibitors (65.2{\%}), calcium channel blockers (52.7{\%}), and corticosteroids (45.3{\%}) were most often prescribed. Among the immunosuppressant agents, cyclophosphamide was used more often in dcSSc than in lcSSc. Conclusions: The EUSTAR database provides an abundance of information on the true clinical face of SSc that will be helpful in improving the classification of SSc and its subsets and for developing more specific therapeutic recommendations.",
author = "Meier, {Florian M P} and Frommer, {Klaus W.} and Robert Dinser and Walker, {Ulrich A.} and L. Czirj{\'a}k and Denton, {Christopher P.} and Yannick Allanore and Oliver Distler and Gabriela Riemekasten and Gabriele Valentini and Ulf M{\"u}ller-Ladner",
year = "2012",
month = "8",
doi = "10.1136/annrheumdis-2011-200742",
language = "English",
volume = "71",
pages = "1355--1360",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "8",

}

TY - JOUR

T1 - Update on the profile of the EUSTAR cohort

T2 - An analysis of the EULAR Scleroderma Trials and Research group database

AU - Meier, Florian M P

AU - Frommer, Klaus W.

AU - Dinser, Robert

AU - Walker, Ulrich A.

AU - Czirják, L.

AU - Denton, Christopher P.

AU - Allanore, Yannick

AU - Distler, Oliver

AU - Riemekasten, Gabriela

AU - Valentini, Gabriele

AU - Müller-Ladner, Ulf

PY - 2012/8

Y1 - 2012/8

N2 - Objectives: Systemic sclerosis (SSc) is a rare disease requiring multicentre collaboration to reveal comprehensive details of disease-related causes for morbidity and mortality. Methods: The European League Against Rheumatism (EULAR) Scleroderma Trials and Research (EUSTAR) group initiated a database to prospectively gather key data of patients with SSc using a minimal essential dataset that was reorganised in 2008 introducing new items. Baseline visit data of patients who were registered between 2004 and 2011 were analysed using descriptive statistics. Results: In June 2011, 7655 patients (2838 with diffuse cutaneous (dc) and 4481 with limited cutaneous (lc) SSc who fulfilled the American College of Rheumatology diagnostic criteria had been registered in 174 centres, mainly European. The most prominent hallmarks of disease were Raynaud's phenomenon (96.3%), antinuclear antibodies (93.4%) and a typical capillaroscopic pattern (90.9%). Scleroderma was more common on fingers and hands than on any other part of the skin. Proton pump inhibitors (65.2%), calcium channel blockers (52.7%), and corticosteroids (45.3%) were most often prescribed. Among the immunosuppressant agents, cyclophosphamide was used more often in dcSSc than in lcSSc. Conclusions: The EUSTAR database provides an abundance of information on the true clinical face of SSc that will be helpful in improving the classification of SSc and its subsets and for developing more specific therapeutic recommendations.

AB - Objectives: Systemic sclerosis (SSc) is a rare disease requiring multicentre collaboration to reveal comprehensive details of disease-related causes for morbidity and mortality. Methods: The European League Against Rheumatism (EULAR) Scleroderma Trials and Research (EUSTAR) group initiated a database to prospectively gather key data of patients with SSc using a minimal essential dataset that was reorganised in 2008 introducing new items. Baseline visit data of patients who were registered between 2004 and 2011 were analysed using descriptive statistics. Results: In June 2011, 7655 patients (2838 with diffuse cutaneous (dc) and 4481 with limited cutaneous (lc) SSc who fulfilled the American College of Rheumatology diagnostic criteria had been registered in 174 centres, mainly European. The most prominent hallmarks of disease were Raynaud's phenomenon (96.3%), antinuclear antibodies (93.4%) and a typical capillaroscopic pattern (90.9%). Scleroderma was more common on fingers and hands than on any other part of the skin. Proton pump inhibitors (65.2%), calcium channel blockers (52.7%), and corticosteroids (45.3%) were most often prescribed. Among the immunosuppressant agents, cyclophosphamide was used more often in dcSSc than in lcSSc. Conclusions: The EUSTAR database provides an abundance of information on the true clinical face of SSc that will be helpful in improving the classification of SSc and its subsets and for developing more specific therapeutic recommendations.

UR - http://www.scopus.com/inward/record.url?scp=84863857123&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863857123&partnerID=8YFLogxK

U2 - 10.1136/annrheumdis-2011-200742

DO - 10.1136/annrheumdis-2011-200742

M3 - Article

VL - 71

SP - 1355

EP - 1360

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 8

ER -